Categories: Top News

METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi’s registration statement for the initial public offering held between February 9, 2024, and May 1, 2024, both dates inclusive (the “Class Period”). Investors have until November 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

The Complaint alleges Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Metagenomi introduced itself to investors during its initial public offering as a “genetic medicines company” having a long-standing business relationship with Moderna, one of the leading Covid-19 vaccine companies and integral to Metagenomi’s collaboration with Moderna was the claim that the two companies had entered into a Strategic Collaboration and License Agreement on October 29, 2021, which included multiple four-year research programs and a subsequent licensed product-by-licensed product agreement.

If you purchased or otherwise acquired Metagenomi shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

GlobeNewswire

GlobeNewswire, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Recent Posts

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…

1 hour ago

Boston Hemp Launches New Line of Premium THCa Concentrates

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…

1 hour ago

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

2 hours ago

Australian Dollar Speculative Net Positions Improve, But Remain in the Negative

The latest data release from the Commodity Futures Trading Commission (CFTC) reveals a marginal improvement…

8 hours ago

Swiss Franc Speculative Positions Narrow as Traders Eye Future Direction

Traders and economists are taking a keen interest in the latest update from the Commodity…

8 hours ago

This website uses cookies.